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Available online 29 June 2016Objectives: This double blinded, placebo controlled randomized clinical trial studies the effect of exenatide on
myocardial infarct size. The glucagon-like peptide-1 receptor agonist exenatide has possible cardioprotective
properties during reperfusion after primary percutaneous coronary intervention for ST-segment elevation
myocardial infarction.
Methods: 191 patients were randomly assigned to intravenous exenatide or placebo initiated prior to percutane-
ous coronary intervention using 10 μg/h for 30min followed by 0.84 μg/h for 72 h. Patients with a previous myo-
cardial infarction, Trombolysis in Myocardial Infarction ﬂow 2 or 3, multi-vessel disease, or diabetes were
excluded. Magnetic resonance imaging (MRI) was performed to determine infarct size, area at risk (AAR)
(using T2-weighted hyperintensity (T2W) and late enhancement endocardial surface area (ESA)). The primary
endpoint was of 4-month ﬁnal infarct size, corrected for the AAR measured in the acute phase using MRI.
Results: After exclusion, 91 patients (age 57.4 ± 10.1 years, 76% male) completed the protocol. There were no
baseline differences between groups. No difference was found in infarct size corrected for the AAR in the
exenatide group compared to the placebo group (37.1 ± 18.8 vs. 39.3 ± 20.1%, p = 0.662). There was also no
difference in infarct size (18.8± 13.2 vs. 18.8± 11.3% of left ventricular mass, p= 0.965). Nomajor adverse car-
diac events occurred during the in-hospital phase.
Conclusion: Exenatide did not reduce myocardial infarct size expressed as a percentage of AAR in ST elevated
myocardial infarction patients successfully treated with percutaneous coronary intervention.
© 2016 Elsevier Ireland Ltd. All rights reserved.Keywords:
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Infarct size1. Introduction
ST elevated myocardial infarction is a leading cause of mortality and
morbidity, caused by acute occlusion of one or more of the epicardial
coronary arteries. Therapy is focussed on fast restoration of antegrade
ﬂow preferably bymeans of a primary percutaneous coronary interven-
tion [1,2]. Successful reperfusion however, paradoxically also induceslume; ESA, endocardial surface
eptide-1; LGE, late gadolinium
SI, myocardial salvage index;
cal trial.
5F-020, VU University Medical
herlands.
.death of cardiomyocytes. This is mediated by a multitude of factors
that eventually culminate in loss of mitochondrial integrity and
hypercontracture, leading to cardiomyocyte death [3]. This phenome-
non is called reperfusion injury and contributes for up to 40% to the
ﬁnal myocardial infarct size [4], which is an important determinant of
clinical outcome in patients with ST elevated myocardial infarction
[5]. Therapies to prevent reperfusion injury are therefore of utmost
importance.
Glucagon-like-peptide-1 (GLP-1) is an incretin hormone with
insulinotropic and insulinomimetic properties. The GLP-1 receptor is
also present on cardiomyocytes and infusion of GLP-1 has been shown
to activate anti-apoptotic pathways and increase myocardial metabolic
efﬁciency in preclinical and clinical studies [6–8].
Exenatide is a long acting GLP-1 receptor agonist and is used widely
for improving glycemic control in patients with type 2 diabetesmellitus
[9]. In preclinical models of myocardial ischaemia and reperfusion
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resulting in reduced infarct size and preserved cardiac function [10,11].
Recently, exenatide therapy was shown to increase myocardial sal-
vage [12] and decrease ﬁnal infarct size [13] in ST elevated myocardial
infarction patients successfully treated with percutaneous coronary in-
tervention. Exenatide is therefore considered one of themost promising
compounds to reduce infarct size [14]. The current study was designed
to investigate the effect of exenatide on myocardial infarct size as a
percentage of the area at risk (AAR) in patients with ST elevated myo-
cardial infarction who underwent successful percutaneous coronary
intervention.
2. Methods
2.1. Overview
The study protocol has been published previously [15]. Thismulti-centre, prospective,
randomized, placebo controlled clinical trial was executed at the VU University
Medical Centre, Amsterdam, and the University Medical Centre Utrecht, Utrecht, the
Netherlands. All patients gave oral informed consent prior to percutaneous coronary inter-
vention andwritten informed consent after percutaneous coronary intervention. The local
ethics committees approved of the protocol. This study was performed in accordance to
the declaration of Helsinki. No ﬁnancial support was provided from the manufacturer.
The study was registered at https://clinicaltrial.gov identiﬁer: NCT01254123.
2.2. Patient population
Consecutive adult patients with ST elevated myocardial infarction with a symptom
duration of less than 6 h were enrolled in the study. Exclusion criteria were primarily: a
known history of diabetes mellitus, prior myocardial infarction or coronary artery by-
pass grafting, a clinically unstable patient (i.e. cardiac shock, ventricular rhythm disor-
ders and Killip class N 1 excluded) and any known contra-indications to magnetic
resonance imaging. Randomization took place using envelops, created by the primary
investigator, in block sizes of 6. A research nurse was unblinded upon enrolment of a
patient to prepare the study medication. The study medication was then transferred
to a blinded nurse, who administered the study medication to the patient. Investigators,
patients and other care providers remained blinded. After randomization to placebo or
exenatide, patients were treated with percutaneous coronary intervention and standard
drug therapy according to local and hospital guidelines valid at the time of admission.
Prior to or during percutaneous coronary intervention, additional exclusion criteria
could arise; patients were excluded if they had multi-vessel disease in need of acute cor-
onary artery bypass grafting or additional percutaneous coronary intervention, because
signiﬁcant multi-vessel disease could potentially have impact on the AAR assessment.
Patients were also excluded if no culprit lesion was found or if the culprit vessel had
Thrombosis in Myocardial infarction 2/3 ﬂow. In these patients, treatment using
exenatide or placebo was discontinued immediately upon reaching one of the angio-
graphic exclusion criteria. The study protocol was continued in patients that remained
eligible for the study after primary percutaneous coronary intervention. The current
study also includes patients enrolled in our pilot safety study [16]. These patients met
the same in- and exclusion criteria.Fig. 1.Measurement of theprimary endpoint. The primary endpoint ofﬁnal infarct size as percen
Contours delineatemyocardial oedema (yellow) and infarct size (red). Arrows point to the regio2.3. Treatment protocol
On admission, patients were immediately randomized to double-blind treatment
with exenatide or placebo. The studymedicationwas prepared as follows: a 50ml syringe
wasﬁlledwith 49ml of NaCl 0.9% and1mlhuman serumalbuminwith orwithout 15 μg of
exenatide, leading to a concentration of 0.3 μg/ml. All patients received a loading
dose (5 μg) in 30 min using a 33.3 ml/h intravenous infusion, followed by a 2.8 ml/h
(20 μg/day) infusion for the remainder of the 3 days. The syringe was replaced every 8 h.
2.4. Study endpoints
The primary endpoint of this study was ﬁnal infarct size measured by magnetic reso-
nance imaging at 4 months after myocardial infarction, expressed as a percentage of the
area at risk (AAR) measured with T2W magnetic resonance imaging in the ﬁrst week
after ST elevatedmyocardial infarction (Fig. 1). Secondary endpoints included ﬁnal infarct
size, myocardial salvage index (MSI), ejection fraction at baseline and 4 months assessed
by magnetic resonance imaging and major adverse cardiac events (major adverse cardiac
events, deﬁned as cardiac death, myocardial infarction, coronary artery bypass grafting or
repeat percutaneous coronary intervention) in 4 months. Creatine kinase muscle brain
wasmeasured on admission and every 6 h following percutaneous coronary intervention.
In the ﬁrst 20 patients treated with exenatide, plasma levels of exenatide were measured
4 h and 24 h after lowering the initial study medication infusion rate.
2.5. Magnetic resonance imaging
Magnetic resonance imaging was performed at 3–7 days after ST elevatedmyocardial
infarction and at 4 months of follow-up. The protocol included Cine, T2 weighted (T2W)
and late gadolinium enhancement (LGE) imaging [15]. Parameters acquired consisted of
left ventricular function (ejection fraction, volumes and left ventricular mass), area at
risk using T2W and the endocardial surface area (ESA), microvascular obstruction
(MVO) and infarct size at baseline. MVO was deﬁned as the low signal intensity region
within the high intensity infarct zone on LGE images. At follow-up, left ventricular function
and infarct size weremeasured. Parameterswere indexed for body surface area and calcu-
lated as percentage of left ventricular mass where applicable. The MSI was calculated in 2
ways: using theAARmeasuredwith T2W imaging (MSIT2W) [17] at baseline and ESAmea-
sured on LGE baseline images (MSIESA) [18]. The formula to determine MSI was (AAR-
infarct size)/AAR. Infarct size wasmeasured in the acute phase (baseline) and at 4months
of follow-up magnetic resonance imaging using LGE images.
2.6. Sample size
With a 5% type 1 error risk, a power of 90% and an anticipated dropout of 10%, 108 pa-
tients (54 per group) were needed to detect a 15% improvement of the primary endpoint.
2.7. Statistical analysis
All patients were analysed using intention to treat protocol. Data was tested for nor-
mal distribution using kurtosis and skewness, values between−2 and 2 were considered
to be normally distributed data. Independent sample t-test was used for continuous vari-
ables. Chi square test and Fisher's exactwere used for categorical data. 1-way ANOVAwith
Bonferroni post-hoc testing was used to compare subgroups of the study population.
Kolmogorov–Smirnov testing was performed when applicable for nonparametric data.tage of theAARwas calculated using T2W images at baseline and LGE images at follow-up.
n of interest. The computer calculated oedema and infarct sizewithin the region of interest.
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3.1. Study population
Between November 2009 and September 2014, a total of 191 out of
412 screened patients with ST elevated myocardial infarction under-
going primary percutaneous coronary intervention ﬁtted the pre-
angiographic inclusion criteria and were randomly assigned to treat-
ment with exenatide or placebo. After percutaneous coronary interven-
tion, 108 patients (51 exenatide, 57 placebo) remained in the study due
to exclusion criteria met during angiography. At follow-up, a 19% drop-
out led to 91 patients (42 exenatides, 49 placebos) that completed the
study protocol. Most dropouts were due to insufﬁcient imaging quality
available for analysis of the primary endpoint (Fig. 2). The trial was
ended as sufﬁcient patients were included before MRI analysis took
place.
There were no baseline differences between both groups (Table 1).
The mean age was 57.4 years and 76% of patients were male. Symp-
tom-to-balloon time was 170 ± 83 vs. 188 ± 91 min (p = 0.35) for
exenatide and placebo respectively. The left anterior descending artery
was culprit artery in 30% of patients. Unfractionated heparin together
with a loading dose of a P2Y12 inhibitor and intravenous aspirin were
administered prior to percutaneous coronary intervention in all patients
according to current European Society for Cardiology guidelines [18].
Glycoprotein IIb/IIIa inhibitors were administered in 30% of patients.Fig. 2. Study ﬂMost percutaneous coronary intervention procedures (90%) resulted
in ﬁnal Thrombolysis in Myocardial Infarction 3 ﬂow. A complete over-
view of procedural data is provided in Table 2.
3.2. Myocardial infarct size and myocardial salvage
The primary endpoint of infarct size as a percentage of the AAR did
not differ between patients treated with exenatide and placebo
(37.1 ± 18.8 vs. 39.3 ± 20.1%, p = 0.662). There was also no difference
in ﬁnal infarct size and myocardial salvage. (Table 3). Infarct location,
body mass index, gender and initial therapeutic treatment differences
showed no confounding effects.
3.3. Other endpoints
There were no differences in baseline and follow-up left ventricular
volumes, functional parameters and occurrence of MVO. A signiﬁcant
difference in left ventricular mass was found, patients that received
exenatide had higher left ventricular masses, but this difference
disappeared after adjusting for body surface area (Table 3). Creatine ki-
nase muscle brain-max was 239 ± 146 and 249 ± 191 μg/l (p = 0.39)
for exenatide and placebo respectively. Median plasma levels of
exenatide 4 h after percutaneous coronary intervention were 0.14
[0.01–1.73] nmol/l.owchart.
Table 1
Baseline characteristics.
Exenatide
(n = 42)
Placebo
(n = 49) p
Age (years) 57.23 (±10.2) 57.48 (±10.1) 0.906
Male (%) 33 (79%) 36 (73%) 0.576
BMI (kg/m2) 27.47 (±4.1) 26.39 (±3.2) 0.167
Body surface area 2.57 (±0.22) 1.99 (±0.20) 0.311
Risk factors
Past/current smoker 18 (45%) 26 (55.3%) 0.688
Hypertension 9 (22.5%) 6 (13.3%) 0.274
Hypercholesterolemia 9 (23.1%) 12 (27.9%) 0.622
Positive family history 18 (43.9%) 26 (56.5%) 0.245
Laboratory results
Haemoglobin (mmol/l) 9.01 (±0.8) 8.87 (±1.6) 0.593
CRP (mg/l)a 3.98 (±3.8) 7.67 (±22.6) 0.357
Cholesterol (mmol/l) 5.56 (±1.1) 5.96 (±1.0) 0.084
Creatinin (μmol/l) 78.9 (±19.0) 77.8 (±23.4) 0.822
eGFR MDRD (ml/min/1.73 m2) 93.8 (±22.4) 94.4 (±33.9) 0.919
NTproBNP (ng/l)a 75.2 (±138.2) 145.9 (±407.8) 0.294
CK-MB max (μg/l)a 326 (±593) 249 (±191) 0.389
CK Max (U/l)a 2510 (±1888) 2650 (±2076) 0.738
Troponin T max (VUmc) (ng/l) 4690 (±4000) 4310 (±5600) 0.76
Troponin I max (UMCU) (ng/l) 36.6 (±38.2) 43.6 (±40.0) 0.694
Blood glucose (mmol/l)a 8.20 (±1.8) 8.01 (±2.1) 0.655
HbA1c (mmol/mol)a 38.59 (±4.4) 39.56 (±5.4) 0.363
Numbers as ‘mean (±SD)’ or ‘n (%)’where applicable. N = number, SD= standard devi-
ation, BMI=bodymass index, Hb=haemoglobin, CRP=C-reactive protein, eGFRMDRD
= estimated glomerular ﬁltration rate modiﬁcation of diet in renal disease, CK-MB =
creatine kinase muscle brain, CK = creatine kinase, HbA1c = haemoglobin A1c.
a Nonparametric Kolmogorov–Smirnov test was used.
Table 3
Imaging results MRI and primary endpoint.
Exenatide Placebo p
LV-EDV (ml, n = 87) 184.15 (±38.44) 174.89 (±40.07) 0.277
LV-ESV (ml, n = 91) 84.54 (±30.71) 81.23 (±34.17) 0.630
LV mass (g) 115.65 (±29.55) 107.46 (±25.27) 0.172
LV-EDV indexed 88.13 (±13.58) 87.61 (±16.64) 0.875
LV-ESV indexed 40.51 (±13.82) 40.65 (±16.30) 0.964
LV mass indexed 55.33 (±11.55) 53.78 (±11.11) 0.529
LV SV (ml) 91.53 (±19.97) 85.54 (±19.16) 0.240
LV EF (%, n = 86) 52.18 (±7.25) 51.17 (±7.35) 0.525
MVO present (n = 79) 19 (50%) 22 (54%) 0.745
AART2W (g, n = 66) 36.79 (±17.54) 31.72 (±18.95) 0.267
MSIESA (n = 73) 0.59 (±0.21) 0.55 (±0.22) 0.491
MSIT2W (n = 66) 0.63 (±0.19) 0.61 (±0.20) 0.662
Follow-up LV-EDV (ml, n = 87) 196.34 (±36.95) 180.72 (±39.33) 0.075
Follow-up LV-ESV (ml, n = 91) 94.78 (±27.98) 87.47 (±29.92) 0.272
Follow-up LV mass (g) 104.46 (±26.08) 89.77 (±22.67) 0.010
Follow-up LV SV (ml) 99.10 (±17.31) 92.65 (±19.62) 0.218
Follow-up LV EF (%, n = 86) 52.42 (±8.34) 52.66 (±8.35) 0.897
Follow-up LV-EDV indexed 93.58 (±14.66) 91.39 (±16.09) 0.532
Follow-up LV-ESV indexed 45.20 (±12.95) 44.01 (±13.59) 0.696
Follow-up LV mass indexed 49.56 (±10.29) 45.31 (±10.05) 0.073
Final infarct size (g, n = 77) 13.12 (±9.21) 12.75 (±9.41) 0.868
Final infarct size as % of LV mass 13.30 (±8.97) 15.06 (±10.53) 0.460
Final infarct size as % of AART2W 37.08 (±18.78) 39.27 (±20.12) 0.662
Numbers as ‘mean (±SD)’ or ‘n (%)’ or ‘mode [±range]’ where applicable. N = number,
SD=standard deviation, BSA=body surface area, LV= left ventricle, EDV=end diastol-
ic volume, ESV = end systolic volume, EF = ejection fraction, MVO =microvascular ob-
struction, AAR = area at risk, ESA = endocardial surface area. EDV, ESV and mass are
corrected for BSA.
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Nausea, a notorious side effect of exenatide, occurred signiﬁcantly
more often in patients receiving exenatide (38 vs 8%, p = 0.001). No
changes had to be made to the infusion rate of study medication in
these patients. Hypoglycaemic episodes occurred equally betweenTable 2
Procedural data from PCI.
Exenatide
(n = 42)
Placebo
(n = 49) p
Treatment pre-PCI 0.451
Heparin 42 49
Aspegic 42 49
Clopidogrel 14 (33%) 11 (22%)
Prasugrel 15 (36%) 25 (51%)
Ticagrelor 13 (31%) 13 (27%)
GP IIb/IIIa treatment 12 (32%) 13 (28%) 0.635
Procedural data
Symptom-to-balloon time (min) 170 (±83) 188 (±91) 0.345
FMC-to-balloon time (min) 73 (±15) 84 (±18) 0.588
Door-to-balloon time (min) 41 (±12) 49 (±19) 0.058
Thrombosuction 36 (86%) 36 (71%) 0.101
Culprit artery 0.585
LAD (%) 13 (31%) 14 (29%)
RCX (%) 6 (14%) 10 (20%)
RCA (%) 23 (55%) 25 (51%)
TIMI grade before procedure 0.738
0 (%) 37 (88%) 42 (86%)
1 (%) 5 (12%) 7 (14%)
TIMI grade after procedure 1.0
2 (%) 4 (9%) 5 (10%)
3 (%) 38 (90%) 44 (90%)
Stent type 0.524
BMS (%) 10 (24%) 9 (18%)
DES (%) 32 (76%) 40 (82%)
Numbers as ‘mean (±SD)’ or ‘n (%)’ or ‘mode [±range]’ where applicable. N = number,
SD= standard deviation, PCI= percutaneous coronary intervention, FMT= ﬁrst medical
contact, LAD= left anterior descending, RCX= right circumﬂex, RCA= right coronary ar-
tery, TIMI = thrombolysis in myocardial infarction, BMS= bare metal stent, DES = drug
eluting stent, GP IIb/IIIa = glycoprotein IIb/IIIa.groups (24 vs 18%, p = 0.53), but hyperglycaemia occurred more
often in the placebo treatment arm (7 vs 20%, p = 0.064) (Table 4).
Two patients receiving exenatide developed an exanthema after N36 h
of infusion, resulting in the preventive cessation of study therapy and
successful administration of an antihistaminic agent. At 4 months of
follow-up, no major adverse cardiac events had occurred. One patient
had received a pacemaker due to AV block.
4. Discussion
In contrast to previous clinical trials using exenatide in ST elevated
myocardial infarction patients, our trial shows no beneﬁt of using
exenatide on top of primary percutaneous coronary intervention in ST
elevated myocardial infarction patients. This may indicate that the
cardioprotective effect of exenatide is less than previously thought, or
that it depends on several speciﬁc conditions. Therefore, it is of utmost
importance to understand the differences between this trial and the
previous studies.
4.1. Trial differences
Two previous trials investigated the cardioprotective effect of
exenatide in patients with ST elevated myocardial infarction undergo-
ing primary percutaneous coronary intervention and reported a beneﬁ-
cial effect on myocardial salvage in a Danish study [12] and ﬁnal infarct
size in a Korean study [13]. Most baseline clinical characteristics,Table 4
Adverse events.
Exenatide
(n = 42)
Placebo
(n = 49) p
Nausea 16 (38%) 4 (8%) 0.001
Need for anti-emetics 14 (33%) 3 (6%) 0.001
Hypoglycaemic episode 10 (24%) 9 (18%) 0.530
Hyperglycaemic episode 3 (7%) 10 (20%) 0.064
MACE 2 (5%) 2 (4%) 0.876
Numbers as ‘mean (±SD)’ or ‘n (%)’ or ‘mode [±range]’where applicable. MACE=major
adverse cardiac events.
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Danish and Korean studies. Another report by Lønborg et al. in 2012
showed that exenatide reduced infarct size in patients with a short sys-
tem delay, i.e. b132 min, and not in patients with a system delay
N132 min [20]. Most likely the ischaemic area is beyond repair if the
ischaemic duration is too long. In our trial the system delay was shorter
(76min vs 132min) and the symptom-to-balloon timewas comparable
with the Danish trial. Despite the short system delay, we were not able
to conﬁrm a cardioprotective effect of exenatide. Other factors must
have played a role.
For example, in our study few patients with anterior infarctions
were included. While the average infarct size as a percentage of AAR
(38%) and ﬁnal infarct size (13 g) were similar to the previously pub-
lished trials, patients included in our trial suffered from anterior infarc-
tions in only 30% of cases, which was 40% in the Danish trial [12]. In the
Danish trial, myocardial salvage was more pronounced in anterior MI
than in non-anterior infarct location. This might be of interest in deter-
mining the exact subgroup of patients with myocardial infarction that
beneﬁts from exenatide treatment.
Our study also included more smokers (Table 1) and fewer patients
were treatedwith glycoprotein (GP) IIb/IIIa inhibitors in our study com-
pared to the Danish study (30% vs 90%; no data provided in the Korean
study). We did not observe an interaction between smoking and
GPIIb/IIIa inhibitors and infarct size, but a relationship cannot be ruled
out because our study was not powered for subgroup analysis.
GP IIb/IIIa inhibitors can be considered in patients if no-reﬂow occurs
after percutaneous coronary intervention [2]. There is evidence for re-
duced infarct size in ST elevated myocardial infarction patients receiv-
ing abciximab [19]. A potential synergistic effect between abciximab
(or other GP IIb/IIIa inhibitors) and exenatide could explain the differ-
ence in outcome between our study and the Danish study.
4.2. Diabetes
Patients with known diabetes mellitus were excluded from our
study, for the arbitrary reason to exclude a potential effect from glucose
control instead of a direct effect on apoptosis. Exenatide might be more
effective in patients with diabetes mellitus, as glucose control might
contribute to an improved clinical outcome [21]. Because of the preclin-
ical evidence, and the relatively low number of patients with diabetes
mellitus in the previous trials (4–9% in the Danish and 25–28% in the
Korean) it is unlikely that exenatidemediated cardioprotection is exclu-
sively present in patients with diabetes mellitus. Consequently, this
does not explain the different outcomes between the clinical trials.
4.3. Underestimation of effect
Furthermore, potential favourable effects of exenatide in this study
might have been underestimated, because of the assessment of the
AAR using T2Wmagnetic resonance imaging. This modality of AAR as-
sessment is based on myocardial oedema. Since exenatide might also
reduce myocardial oedema, the AAR could have been underestimated
in the exenatide treatment arm, and therefore the infarct size in relation
to the AAR was overestimated. This effect might be enhanced by the
time-dependence of oedema in the ﬁrst week after ST elevatedmyocar-
dial infarction that adds to the large variability of AAR assessment using
T2W imaging [22]. Lønborg et al. however used the same modality and
observed a favourable effect of exenatide. Also, the ESA does not have
these limitations and also did not showa difference between our patient
groups.
4.4. Treatment protocol
The most obvious difference between the trials is the exenatide
treatment protocol. Our initial bolus dose was chosen based on
our unpublished previous experience with healthy subjects and wasdemonstrated to be the highest well tolerated dose, not inducing severe
nausea. The maintenance dose and duration were based on results of
our previous preclinical study [11] and a clinical study with GLP-1 [7],
in order to achieve a potential beneﬁcial effect on metabolic efﬁciency
and cardiac function. We previously demonstrated this protocol to be
safe and feasible for application in patients with ST elevated myocardial
infarction [16].
We administered an exenatide bolus of 5 μg in 30min IV followed by
an infusion of 20 μg per day for 3 days, whereas by Lønborg et al. an ini-
tial bolus of 1.8 μg IV (in 15 min) was given and another infusion of
15.5 μg over the next 6 h. These protocols resulted in exenatide plasma
levels of 0.01–1.73 nmol/l (mean 0.14 nmol/l, measured 4 1/2 h after
initiation of treatment) in our study and of 0.1–0.39 nmol/l (mean
0.177 nmol/l; measured 15 min after initiation of the treatment) in
the Danish study. Unfortunately, plasma levels cannot be easily com-
pared due to the different time points. Woo et al. treated patients with
a 10 μg exenatide bolus intravenously and a 10 μg subcutaneous dose
5 min before reperfusion, followed by a 10 μg twice daily subcutaneous
injection for three days, in accordance with our preclinical study [11],
but plasma levels were not measured.
The cascade of events resulting in reperfusion injury is initiated in
theﬁrstminutes after reperfusion [3]. Therefore it is important to obtain
a therapeutic plasma level before the onset of reperfusion. In all 3 stud-
ies, the treatment was initiated before reperfusion. Woo et al. adminis-
tered the highest intravenous dose before reperfusion (10 μg). In the
Danish study, all participants received at least 1.8 μg before reperfusion.
On average, our 42 patients in the treatment arm received 4.82 (±1.09)
μg of exenatide prior to balloon inﬂation. Thus, a higher dose of
exenatide was administered before reperfusion in our study than in
the Danish study. Nonetheless, the Danish investigators observed a re-
duction in myocardial infarct size, whereas we did not. A biphasic
dose–effect relationship of exenatide has been suggested for exenatide
in an isolated rat heart model, with a loss of a cardioprotective effect
with plasma levels exceeding 3.0 nmol/l [10]. Unfortunately, we do
not have exenatide plasma levels available around the time of reperfu-
sion. It cannot be ruled out that plasma levels were too high, possibly
resulting in a loss of cardioprotection. However, in the Korean study
byWoo et al. even a higher intravenous dose of 10 μg was administered
before reperfusion. Although no correctionwasmade for the AAR in this
study, the reduction in ﬁnal infarct size suggests a cardioprotective ef-
fect of exenatide using a very high bolus dose. Another possibility is
that exenatide exerts its most important cardioprotective actions not
so much in the ﬁrst minutes, but in the ﬁrst hours after reperfusion.
Both Lønborg and Woo administered a higher total dose in the ﬁrst
6 h after reperfusion than we did in the present study.
4.5. Tolerability
An important concern regarding a high treatment dose is the tolera-
bility. Nausea is awell-known side effect of exenatide described to occur
in up to 40–50% of the patients [23]. Severe nausea requiring the need
for anti-emetics in most cases occurred in 38% of the patients receiving
exenatide in this study, following the initial 30 min bolus dose, versus
8% in patients receiving placebo. The previous studies do not report
data on the occurrence of nausea.
5. Limitations
Due to a higher dropout than expected the number of patients that
was included in the ﬁnal analysis was slightly lower than anticipated.
However, the ﬁnal endpoints are all comparable between exenatide
and placebo without any trend towards a cardioprotective effect of
exenatide. Expansion of the groups is therefore unlikely to change the
interpretation of the results. A new power analysis based on the results
from this study shows that a sample size of 1161 patients per group
would be needed to meet a difference in the primary endpoint. Our
814 S.T. Roos et al. / International Journal of Cardiology 220 (2016) 809–814exclusion rate in this study is relatively high, due to the fact that we
aimed to acquire a population without multiple confounding factors
such as multi-vessel disease, in order to determine the maximum ther-
apeutic effect of exenatide. Also, our initial dropout of 221 patients was
mostly due to a high rate of patient refusal. These factors have caused
our results to be only moderately applicable to the real world situation.
6. Conclusion
In this study, exenatide treatment did not result in reduction ofmyo-
cardial infarct size as a percentage of the AAR in ST elevatedmyocardial
infarction patients successfully treated with percutaneous coronary
intervention. Additional studies are warranted to unravel the reasons
for the ambiguous trial results and to identify an optimal treatment
protocol.
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